重要内容提示： （网址：http://roadshow.sseinfo.com） 说明会议召开方式：视频和网络文字互动 投资者可于 2023 年 4 月 25 日（星期二）16:00 前登录上证路演中心网站首页 点击"提问预征集"栏目或通过公司邮箱 ir@cansinotech.com 进行提问。公司将 在说明会上对投资者普遍关注的问题进行回答。 康希诺生物股份公司（以下简称"公司"）于 2023 年 3 月 28 日发布公司 2022 年年度报告，为便于广大投资者更全面深入地了解公司 2022 年年度经营成果、 财务状况，公司参与了由上海证券交易所主办的 2022 年度生物制品专场集体业 绩说明会，此次活动将采用视频和网络文字互动的方式举行，投资者可登录上海 证券交易所上证路演中心（http://roadshow.sseinfo.com/）参与线上互动交流。 一、说明会类型 证券代码：688185 证券简称：康希诺 公告编号：2023-022 康希诺生物股份公司 关于参加 2022 年度生物制品专场集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其 ...

Financial Performance - The company reported a net loss for the year 2022, continuing its trend of unprofitability since its IPO[2]. - The company reported a revenue of 1.5 billion in 2022, representing a year-over-year growth of 20%[166]. - The company provided a forward guidance of 1.8 billion in revenue for 2023, expecting a growth rate of 20%[166]. - The company’s net profit attributable to shareholders turned to a loss due to a substantial decline in COVID-19 vaccine sales revenue compared to the same period last year[86]. - The company reported a net cash flow from operating activities of -1,851,545 thousand RMB, a decrease of 190.32% compared to the previous year[67]. - The company’s cash and cash equivalents decreased by 38.62% to 3,464,734 thousand RMB compared to the previous year[71]. - The company’s investment activities resulted in a net cash flow of -1,227,641 thousand RMB, a decrease of 52.05% from the previous year[67]. - The company reported a significant increase in short-term borrowings, rising by 54.42% to 1,529.8 million[85]. - The company’s long-term borrowings increased dramatically by 2,095.02% to 878.0 million, primarily due to new loans for special projects and working capital[85]. - The company’s total sales revenue from major customers reached 520,329 thousand RMB, accounting for 40.49% of total annual sales[64]. Research and Development - The company is focused on the research and development of vaccines and related biotechnologies, aiming to expand its product offerings[34]. - The company has developed a universal mRNA technology that significantly shortens product development time and facilitates rapid industrialization[46]. - The company has established various carrier protein production technologies and coupling techniques for polysaccharide vaccines, enhancing the quality of its multivalent and combination vaccines[45]. - The R&D pipeline includes vaccines for COVID-19, meningitis, Ebola, diphtheria, pertussis, tuberculosis, and shingles, addressing urgent clinical needs[152]. - R&D investment for the mRNA COVID-19 vaccine amounted to CNY 130,415,000, representing 12.61% of total revenue, with a year-over-year increase of 119.11%[114]. - The company has improved existing vaccine products through gene engineering and protein engineering, significantly enhancing antigen yield and simplifying production processes[128]. - The company has developed an inhaled recombinant novel coronavirus vaccine (5-type adenovirus vector) for COVID-19 prevention[92]. - The company has developed a recombinant COVID-19 vaccine (Ad5 vector) and is progressing on a tuberculosis booster vaccine (Ad5Ag85A), leveraging its adenovirus vector technology platform[128]. - The company completed Phase IIb clinical trials for its mRNA COVID-19 vaccine and Phase III clinical trials for the PCV13 vaccine[96]. - The PCV13 vaccine development costs were partially capitalized, with CNY 11,625,000 recognized as capitalized expenses[114]. - The DTcP vaccine's R&D investment was CNY 19,337,000, accounting for 1.87% of total revenue, with a year-over-year increase of 42.12%[114]. - The TB vaccine has completed Phase Ib clinical trials, indicating progress in its development[96]. Market and Strategic Developments - The company plans to invest hundreds of millions in vaccine development, facing risks of potential failures in final development[39]. - The company is actively expanding its marketing network and enhancing its cold chain logistics to improve product penetration[117]. - The company is focusing on importing high-quality vaccines to replace existing products in developed markets, with MCV4 being the first approved product in China using the CRM197 carrier protein[140]. - The company plans to enhance its customer engagement through improved digital platforms, aiming for a 25% increase in customer satisfaction scores[166]. - The company is considering strategic acquisitions to bolster its market position, with a budget of 200 million allocated for potential deals[166]. - The company is involved in various related party transactions as per the annual report[182]. - The company has established agreements to ensure compliance with shareholder obligations, reflecting a commitment to governance[160]. - The company is committed to operational management and strategic development, as highlighted by the roles of its executive team[161]. - The company aims to deepen its R&D platform management and explore global cooperation opportunities to enhance long-term operational and profitability capabilities[142]. - The company is actively engaging in corporate governance improvements, including revisions to internal management systems[177]. Governance and Management - The audit report issued by Deloitte Huayong confirmed the financial statements with a standard unqualified opinion[7]. - The company has established specialized committees, including an audit committee, nomination committee, and compensation and assessment committee, to enhance governance[189]. - The company has a strong leadership team with extensive experience in the biotechnology and pharmaceutical industries[161]. - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period was 37,487[197]. - The total remuneration for core technical personnel at the end of the reporting period was 24,374[197]. - The company has not reported any changes in shareholding for its non-executive directors during the reporting period[158]. - The company has not faced any penalties from securities regulatory agencies in the past three years[176]. - The company has implemented a plan for share repurchase through centralized bidding, reflecting its commitment to shareholder value[198]. - The company has not identified any risks during the supervisory review conducted by the supervisory board[191]. - The company has a diverse workforce, with 32 employees holding doctoral degrees and 416 holding master's degrees[193]. Operational Challenges and Risks - The company highlighted significant risk factors that could adversely affect its operations, urging investors to be cautious[12]. - The company has not encountered any non-operational fund occupation by controlling shareholders or related parties[29]. - The company’s inventory of COVID-19 vaccines was subject to impairment provisions due to market conditions, leading to increased sales expenses[86]. - The management discussed future plans and strategic developments, emphasizing the importance of risk awareness in investment decisions[8]. - The company has established a drug safety monitoring system to ensure public medication safety[78]. - The company has not disclosed any plans for profit distribution or capital increase through reserves during the reporting period[13]. Charitable Activities - The company made charitable donations totaling 1.18 million, including 1.13 million to foundations and 0.136 million for rural revitalization and pandemic support activities[91].

Revenue and Profit Performance - Revenue for Q3 2022 was RMB 77,605 thousand, a decrease of 92.42% compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2022 was a loss of RMB 486,649 thousand, a decline of 222.65% year-over-year[2] - The significant decline in revenue and profit was primarily due to a substantial decrease in demand for COVID-19 vaccines compared to the previous year[5] - Total operating revenue for the first three quarters of 2022 was 707,395 thousand RMB, a decrease from 3,085,775 thousand RMB in the same period of 2021[17] - Net profit for the first three quarters of 2022 was -488,682 thousand RMB, compared to a net profit of 1,333,896 thousand RMB in the same period of 2021[21] - Basic and diluted earnings per share for the first three quarters of 2022 were -1.92 RMB, compared to 5.39 RMB in the same period of 2021[22] Research and Development - R&D expenses for Q3 2022 totaled RMB 229,531 thousand, an increase of 111.18% compared to the same period last year[3] - R&D expenses accounted for 295.77% of revenue in Q3 2022, an increase of 285.16 percentage points year-over-year[3] - Research and development expenses for the first three quarters of 2022 were 549,066 thousand RMB, a decrease from 655,770 thousand RMB in the same period of 2021[19] Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date period was RMB -1,393,278 thousand, a decrease of 212.07% compared to the same period last year[3] - Cash flow from operating activities for the first three quarters of 2022 was -1,393,278 thousand RMB, compared to 1,243,273 thousand RMB in the previous year[24] - The net increase in cash and cash equivalents for Q3 2022 was -2,490,640[25] - The beginning cash and cash equivalents balance was 5,455,456[25] - The ending cash and cash equivalents balance was 2,964,816[25] Assets and Liabilities - Total assets at the end of the reporting period were RMB 11,539,285 thousand, a decrease of 2.82% from the end of the previous year[3] - The company's cash and cash equivalents decreased to RMB 2,969,159 thousand from RMB 5,645,030 thousand, representing a decline of about 47.4%[13][15] - The total liabilities of the company as of September 30, 2022, were RMB 3,784,224 thousand, up from RMB 3,326,303 thousand, reflecting an increase of about 13.8%[16] - The company's equity attributable to shareholders decreased to RMB 7,216,494 thousand from RMB 7,995,046 thousand, a decline of approximately 9.7%[16] - The company recognized an impairment provision of RMB 526,175.9 thousand for inventory related to COVID-19 vaccines due to a significant decrease in demand compared to 2021[11] Inventory and Receivables - Inventory as of September 30, 2022, was RMB 880,460 thousand, slightly up from RMB 875,621 thousand in the previous year, indicating a marginal increase of 0.1%[13][15] - The company reported accounts receivable of RMB 312,013 thousand, which increased from RMB 157,926 thousand, showing a growth of about 97.5%[13][15] Other Financial Metrics - The weighted average return on equity was -6.53%, a decrease of 12.03 percentage points year-over-year[3] - The company reported a basic and diluted earnings per share of -RMB 1.97 for Q3 2022, a decline of 223.10% compared to the same period last year[3] - The total amount of non-recurring gains and losses for Q3 2022 was RMB 39,165 thousand[4] - Cash inflow from investment activities for the first three quarters of 2022 was 9,360,944 thousand RMB, significantly higher than 3,968,365 thousand RMB in the same period of 2021[24] - Cash outflow from investment activities for the first three quarters of 2022 was 11,284,530 thousand RMB, compared to 6,201,509 thousand RMB in the previous year[24] - Net cash flow from financing activities for the first three quarters of 2022 was 628,605 thousand RMB, down from 1,397,063 thousand RMB in the same period of 2021[24] - The company reported a tax expense of -158,171 thousand RMB for the first three quarters of 2022, compared to -43,506 thousand RMB in the previous year[19]

Financial Performance - Cansino reported a total revenue of RMB 1.2 billion for the first half of 2022, representing a year-on-year decrease of 30%[1]. - The company’s net loss for the period was RMB 500 million, compared to a net profit of RMB 200 million in the same period last year[1]. - The company's revenue for the first half of 2022 was CNY 629.79 million, a decrease of 69.45% compared to CNY 2,061.46 million in the same period last year[14]. - The net profit attributable to shareholders was CNY 12.24 million, down 98.69% from CNY 937.13 million year-on-year[14]. - The net cash flow from operating activities was negative CNY 1,213.52 million, a decline of 257.90% compared to CNY 768.52 million in the previous year[14]. - The company has set a revenue guidance of RMB 2.5 billion for the full year 2022, reflecting a cautious outlook due to market conditions[1]. - The company achieved revenue of RMB 629,790 thousand, a decrease of 69.45% compared to the same period last year[56]. - Net profit attributable to shareholders was RMB 12,238 thousand, down 98.69% year-on-year[56]. - The total assets increased by 0.97% to RMB 11,989,097 thousand, while net assets attributable to shareholders decreased by 3.69% to RMB 7,700,245 thousand[56]. Research and Development - Cansino is investing RMB 300 million in R&D for new vaccine technologies, aiming to launch two new products by 2024[1]. - The R&D expenditure accounted for 51.80% of the revenue, an increase of 24.31 percentage points compared to 27.49% in the previous year[15]. - The company has developed a pipeline of 17 innovative vaccines targeting various diseases, including COVID-19 and Ebola, with several products already receiving emergency use authorization[19]. - The company has established five major technology platforms for vaccine research, showcasing its strong R&D capabilities[26]. - The company reported a total R&D investment of CNY 326,226 thousand, a decrease of 42.44% compared to the previous year, with a significant drop in capitalized R&D investment by 85.37%[32]. - The company is advancing multiple vaccine projects, including the Ad5-nCoV COVID-19 vaccine with a total investment of CNY 1,130,000 thousand, which has received emergency use authorization in several countries[33]. - The company has established a comprehensive quality management system that meets international standards for vaccine production, ensuring the safety and quality of its products[37]. Market Expansion and Strategy - User data indicates that Cansino's vaccine distribution reached 100 million doses globally, with a significant portion in emerging markets[1]. - The company plans to expand its market presence in Southeast Asia and Latin America, targeting a 20% increase in market share by the end of 2023[1]. - Cansino is exploring strategic partnerships for potential mergers and acquisitions to enhance its product pipeline and market reach[1]. - The company has deepened international cooperation, including a partnership with Malaysia's National Institute of Biotechnology and Solution Biologics for vaccine development and commercialization[50]. Financial Position and Cash Flow - Cansino's cash reserves stand at RMB 1 billion, providing a buffer for ongoing operations and strategic initiatives[1]. - The company reported a non-recurring gain of RMB 33,665 thousand from government subsidies closely related to its normal business operations[17]. - The total amount of financial assets measured at fair value reached 3,293,370 thousand RMB, up from 1,907,985 thousand RMB[63]. - The company has ongoing property leases with various entities, with total lease amounts including RMB 202,967,000 and RMB 11,368,000 for different properties[112]. - The company has utilized CNY 250 million for supplementary working capital, achieving 100% of the planned investment[117]. Risks and Challenges - The company has identified key risk factors, including regulatory changes and competition, which may impact future performance[1]. - The global vaccination rate is expected to slow down, leading to increased market competition and potential price declines for COVID-19 vaccines[51]. - The company faces significant risks, including potential performance declines due to R&D project setbacks and increased competition from larger firms[52]. Environmental and Governance Practices - The company has established an environmental management system and has not faced any administrative penalties for environmental violations as of the reporting period[70]. - The company is committed to low-carbon production and has taken measures such as equipment upgrades and increased use of renewable energy to reduce carbon emissions[73]. - The company has made commitments regarding share lock-up periods, with major shareholders agreeing not to transfer or reduce their holdings for 36 months post-IPO, ensuring stability in the share structure[75]. Shareholder and Equity Information - The company has established a plan to stabilize A-share prices for three years post-IPO, which includes potential stock buybacks[88]. - The company will adhere to the specific implementation plan for stabilizing stock prices if certain conditions are met within three years of the IPO[89]. - The company has committed to not reducing its holdings of A-shares for three complete accounting years if it has not achieved profitability post-IPO[85]. - The company has outlined specific commitments related to share incentives, ensuring that the vesting of restricted stock awards aligns with performance metrics over a maximum period of 48 months[76]. Compliance and Accounting Policies - The financial statements are prepared based on the accrual basis of accounting, with historical cost as the measurement basis for most assets and liabilities[163]. - The company’s financial statements for the first half of 2022 comply with the requirements of the accounting standards and reflect the financial position as of June 30, 2022[166]. - The group recognizes foreign exchange differences arising from foreign currency transactions directly in the current profit and loss, except for those related to capitalized assets[175].

Financial Performance - Total revenue for Q1 2022 was RMB 499,355 thousand, representing a year-on-year increase of 6.98%[2] - Net profit attributable to shareholders was RMB 121,413 thousand, with basic and diluted earnings per share both at RMB 0.49[2] - Operating profit for Q1 2022 was RMB 121,874 thousand, a significant recovery from a loss of RMB 16,190 thousand in Q1 2021[16] - Net profit for Q1 2022 amounted to RMB 114,295 thousand, compared to a loss of RMB 15,752 thousand in Q1 2021[16] - The net profit attributable to shareholders of the parent company was 121,413,000, compared to a net loss of 14,114,000 in the previous period[17] - The total comprehensive income attributable to shareholders of the parent company was 121,413,000, while the comprehensive income attributable to minority shareholders was -7,118,000, compared to -1,638,000 in the previous period[17] - The basic and diluted earnings per share were both 0.49 yuan, compared to a loss of 0.06 yuan per share in the previous period[17] Research and Development - R&D investment totaled RMB 159,416 thousand, a decrease of 40.91% compared to the previous year[2] - R&D expenses accounted for 31.92% of total revenue, a decrease of 25.88 percentage points year-on-year[3] - Research and development expenses for Q1 2022 were RMB 157,155 thousand, a decrease of 41.7% from RMB 269,788 thousand in Q1 2021[16] Cash Flow and Liquidity - The net cash flow from operating activities was negative at RMB -598,148 thousand, primarily due to longer collection cycles and increased cash payments for raw materials and employee salaries[2][5] - Cash inflows from operating activities totaled 230,369,000, down from 525,180,000 in the previous period[19] - Cash outflows from operating activities amounted to 828,517,000, compared to 537,596,000 in the previous period[19] - The net cash flow from investment activities was -894,010,000, compared to 8,094,000 in the previous period[20] - The net increase in cash and cash equivalents was -1,481,585,000, compared to an increase of 232,336,000 in the previous period[20] Assets and Liabilities - Total assets at the end of the reporting period were RMB 11,933,983 thousand, a slight increase of 0.50% from the end of the previous year[3] - Non-current assets totaled RMB 2,811,478 thousand, an increase of 8.8% from RMB 2,584,343 thousand year-over-year[15] - Current liabilities decreased to RMB 2,774,427 thousand from RMB 2,861,417 thousand, reflecting a reduction of 3.0%[15] - Long-term borrowings increased to RMB 155,000 thousand from RMB 40,000 thousand, indicating a rise of 287.5%[15] - Total equity attributable to shareholders rose to RMB 8,034,486 thousand, compared to RMB 7,995,046 thousand in the previous year[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 24,318[7] - Major shareholders included HKSCC NOMINEES LIMITED with a 39.63% stake and Xuefeng Yu with a 7.22% stake[7] - The company has approved a share repurchase plan with a total amount not less than RMB 150 million and not exceeding RMB 300 million, with a repurchase price cap of RMB 446.78 per share[12] - The company has repurchased a total of 325,000 A shares through the Shanghai Stock Exchange as of March 31, 2022[12] Product Development and Market Outlook - The company’s new COVID-19 vaccine, Kweisha®, received domestic approval for sequential booster immunization in February 2022 and is undergoing WHO GMP certification[10] - The global vaccination rate is expected to slow down, with increased competition in the COVID-19 vaccine market leading to potential price declines[11] - The company is in the process of including Kweisha® in the WHO's Emergency Use Listing (EUL) following its approval[10] Other Financial Metrics - Non-recurring gains and losses totaled RMB 39,199 thousand, including government subsidies of RMB 22,264 thousand and fair value changes of financial assets of RMB 21,010 thousand[4] - The weighted average return on equity was 1.51%[2] - The company's cash and cash equivalents decreased to RMB 4,290,250, down from RMB 5,645,030 in the previous year, representing a decline of approximately 24%[13] - The total current assets amounted to RMB 9,122,505, a slight decrease from RMB 9,289,844 in the previous year, indicating a reduction of about 1.8%[13] - The company's inventory increased to RMB 1,121,661, up from RMB 875,621, reflecting a growth of approximately 28%[13] - The accounts receivable rose significantly to RMB 350,532, compared to RMB 157,926 in the previous year, marking an increase of about 122%[13]

Financial Performance - Cansino Biologics reported a cash dividend of 8 RMB per 10 shares, totaling approximately 197.7 million RMB for distribution [4]. - The company has not achieved profitability since its listing, indicating ongoing financial challenges [3]. - The company received a standard unqualified audit report from Deloitte Huayong [3]. - The company's operating revenue for 2021 reached CNY 4,299,702 thousand, a significant increase of 17,174.82% compared to CNY 24,890 thousand in 2020 [18]. - The net profit attributable to shareholders of the listed company was CNY 1,914,390 thousand in 2021, recovering from a loss of CNY 396,638 thousand in 2020 [18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 1,797,038 thousand, compared to a loss of CNY 511,332 thousand in the previous year [18]. - The net cash flow from operating activities was CNY 2,049,999 thousand, a recovery from a negative cash flow of CNY 349,934 thousand in 2020 [18]. - The total assets of the company increased to CNY 11,874,187 thousand at the end of 2021, representing a growth of 75.96% from CNY 6,748,073 thousand at the end of 2020 [18]. - The net assets attributable to shareholders of the listed company were CNY 7,995,046 thousand at the end of 2021, up 31.70% from CNY 6,070,854 thousand at the end of 2020 [18]. - The company reported a weighted average return on equity of 27.21%, a significant improvement from -13.49% in the previous year [19]. - The gross margin for vaccine products was 69.85%, with a year-on-year increase of 27.46 percentage points [82]. - The company achieved operating revenue of 4,299,702 thousand RMB, representing a year-on-year growth of 17,174.82% [78]. - The net profit attributable to shareholders was 1,914,390 thousand RMB, marking a turnaround from loss to profit [78]. - Total assets increased by 75.96% to 11,874,187 thousand RMB compared to the beginning of the year [78]. Research and Development - The company is focused on the development of various vaccines, including mRNA vaccines and inactivated vaccines, to enhance its product portfolio [17]. - Research and development expenses accounted for 21.05% of operating revenue, indicating a strong commitment to innovation [19]. - The company has 17 innovative vaccine products in its pipeline, targeting 12 indications, with several in clinical trial stages [26]. - The company has developed a pipeline of 17 innovative vaccines targeting 12 indications, including COVID-19, Ebola, meningitis, and tuberculosis [34]. - The company is in the preclinical research phase for several new vaccines, including mRNA COVID-19 and adenovirus vaccines [35]. - The company has established five major technology platforms for vaccine development, showcasing its advanced capabilities in the vaccine industry [50]. - The company reported a significant increase in research and development (R&D) expenditures, totaling CNY 904,910 thousand, a 111.14% increase compared to the previous year [58]. - The company’s total R&D investment accounted for 21.05% of its operating income [58]. - The company has made significant progress in developing various vaccines, including those for tuberculosis and other infectious diseases [51]. - The company is actively advancing clinical trials for its pipeline products, indicating a commitment to ongoing innovation and development [111]. Market Expansion and Strategy - The company is actively pursuing market expansion strategies to increase its market share in the biopharmaceutical sector [17]. - The company has established a strong presence in the vaccine market, with ongoing research and development efforts aimed at expanding its product offerings [17]. - The company is enhancing its marketing and management systems to support product commercialization and brand image [33]. - The company is expanding its sales team and building a cold chain logistics network to ensure high-quality vaccine distribution [36]. - The company is focusing on the development of high-quality vaccines to replace imported products, with MCV4 being the first approved product in China using the CRM197 carrier protein [126]. - The company plans to enhance its digital marketing strategy, expecting a 25% increase in online sales as a result [135]. - The company aims to establish a marketing system primarily based on its own sales team, with potential partnerships to penetrate county-level markets [129]. Corporate Governance and Compliance - The board of directors confirmed the absence of significant risks that could adversely affect the company's operations [3]. - There are no special arrangements for corporate governance applicable to the company [6]. - The company has established a governance structure compliant with regulatory requirements, ensuring effective operation and accountability [130]. - The company has not reported any rejected proposals during the shareholders' meetings, indicating a consensus among shareholders [133]. - The company has established a fair and transparent promotion mechanism for employee career development [164]. - The company has implemented a registration management system for insider information to prevent insider trading [198]. Environmental and Social Responsibility - The company aims to achieve zero days of exceeding discharge standards for wastewater, focusing on reducing biochemical oxygen demand (BOD), chemical oxygen demand (COD), and ammonia nitrogen (NH3) [182]. - The company has not been listed as a key pollutant discharge unit and did not receive any administrative penalties for environmental issues during the reporting period [176][177]. - The company donated a total of 5.95 million CNY (approximately 0.95 million USD) for various charitable activities, including 5 million CNY for disaster relief in Henan province [187][188]. - The company adheres to the United Nations Sustainable Development Goals (SDGs) and emphasizes the importance of environmental protection and sustainable supply chain management [175]. Employee and Management - The workforce increased to 1,946 employees by the end of the reporting period, bolstering the company's operational and innovative capabilities [32]. - The company has a diverse workforce, including 804 production staff, 232 sales personnel, 309 R&D staff, and 283 management personnel [162]. - The total remuneration for all directors, supervisors, and senior management personnel at the end of the reporting period amounted to 31,664,000 RMB [148]. - The company provides competitive compensation packages, including year-end performance bonuses and various benefits exceeding legal standards [163]. - The company has established a remuneration policy that adheres to relevant laws and provides social insurance and housing fund contributions [163]. Risks and Challenges - The management has highlighted potential risks associated with forward-looking statements regarding future plans and strategies [5]. - The company faces risks related to potential significant losses if R&D projects do not meet expectations or if new technologies emerge that could render its products obsolete [70]. - The ongoing COVID-19 pandemic presents uncertainties that could hinder the commercialization of related products [77]. - The company is exposed to foreign exchange risks related to overseas product exports, which could affect operational performance [73]. - The company faced competitive pressures from large multinational and domestic vaccine companies, which may impact future performance if product optimization and sales network enhancements are not maintained [72].

Financial Performance - The company's operating revenue for Q3 2021 was ¥1,024,320,530.52, representing a year-on-year increase of 62,199.88%[2]. - The net profit attributable to shareholders for the same period was ¥396,762,938.64, with a year-to-date net profit of ¥1,333,895,747.93, indicating a significant turnaround[2][4]. - Total revenue for the first three quarters of 2021 reached ¥3,085,775,466.38, a significant increase from ¥5,673,787.90 in the same period of 2020[14]. - Operating profit for the third quarter was ¥1,295,250,887.58, compared to a loss of ¥176,696,651.33 in the previous year[15]. - Net profit for the third quarter amounted to ¥1,333,895,747.93, a substantial recovery from a net loss of ¥175,891,311.14 in the same quarter of 2020[15]. - Basic earnings per share for the third quarter were ¥5.39, a recovery from a loss of ¥0.78 per share in the same quarter of 2020[16]. - The company reported a tax expense of ¥43,506,032.42 for the third quarter, reflecting its profitability[15]. Assets and Liabilities - The total assets at the end of the reporting period reached ¥10,885,218,247.28, reflecting a 61.31% increase from the previous year[4][6]. - Total assets as of the end of the third quarter were ¥10,885,218,247.28, compared to ¥6,748,073,711.72 at the same time last year[12]. - Total liabilities increased to ¥3,465,059,903.72 from ¥677,219,551.36 year-over-year, reflecting growth in financial obligations[12]. - The company's equity attributable to shareholders reached ¥7,420,158,343.56, up from ¥6,070,854,160.36 in the previous year[13]. Cash Flow - The company reported a net cash flow from operating activities of ¥474,750,433.68 for the quarter, compared to a net outflow in the same period last year[4][6]. - The net cash flow from operating activities for the first three quarters of 2021 was approximately ¥1.24 billion, a significant improvement from a net outflow of approximately ¥171.97 million in the same period of 2020[17]. - Cash inflow from investment activities totaled approximately ¥3.97 billion, compared to ¥2.58 billion in the previous year[18]. - The net cash flow from investment activities was a negative ¥2.23 billion, an improvement from a negative ¥3.28 billion in the same period of 2020[18]. - Cash inflow from financing activities was approximately ¥1.58 billion, down from approximately ¥4.98 billion in the previous year[18]. - The net increase in cash and cash equivalents for the period was approximately ¥418.77 million, compared to an increase of approximately ¥1.48 billion in the same period of 2020[18]. - The total cash and cash equivalents at the end of the period stood at approximately ¥4.86 billion, up from approximately ¥1.68 billion at the end of the same period last year[18]. Research and Development - Research and development expenses totaled ¥108,690,828.22, accounting for 10.61% of operating revenue, a decrease of 4166.97 basis points compared to the previous year[4][6]. - Research and development expenses for the third quarter totaled ¥655,770,308.43, up from ¥176,716,264.71 in the previous year, indicating a focus on innovation[15]. - The company plans to continue increasing R&D investment to maintain its technological and quality advantages in future products[6]. - The company plans to enhance its synthetic biology vaccine technology platform and accelerate the R&D and industrialization of innovative vaccines[9]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 19,018[6]. - The total number of shares held by the top 10 unrestricted shareholders was 98,067,097, with HKSCC NOMINEES LIMITED holding the largest share at 39.63%[8]. Inventory and Current Assets - As of September 30, 2021, the company's total current assets reached ¥8,569,985,663.65, an increase from ¥5,420,643,756.35 in the previous year, representing a growth of approximately 58.5%[10]. - The cash and cash equivalents amounted to ¥5,139,096,202.52, up from ¥4,447,029,798.94, indicating a year-over-year increase of about 15.6%[10]. - The company's inventory increased significantly to ¥590,097,330.71 from ¥170,512,571.77, reflecting a growth of approximately 246.5%[11]. - The total non-current assets as of September 30, 2021, were ¥2,315,232,583.63, compared to ¥1,327,429,955.37 in the previous year, marking an increase of about 74.6%[11]. - The company's trading financial assets increased to ¥1,985,695,589.05 from ¥666,639,616.43, showing a growth of approximately 197.5%[11]. - Accounts receivable rose to ¥481,556,188.09 from ¥22,143,420.00, representing a significant increase of about 2065.5%[11]. New Developments - The company established a new subsidiary, 康希诺（上海）生物科技有限公司, to accelerate the development of an innovative vaccine research and production base in Shanghai[9]. - The self-developed A group C group meningococcal polysaccharide conjugate vaccine (CRM197 carrier) received its first batch release certificate, indicating its official market launch in China[9]. - The company recognized non-recurring gains of ¥21,327,598.48 in the quarter, primarily from government subsidies and fair value changes of financial assets[5].

Financial Performance - The company reported a total revenue of RMB 1.5 billion for the first half of 2021, representing a year-on-year increase of 25%[1]. - The company achieved a revenue of CNY 2,061,454,935.86 in the first half of 2021, representing a significant increase of 51,057.67% compared to the same period last year[12]. - The net profit attributable to shareholders was CNY 937,132,809.29, a substantial recovery from a loss of CNY 102,201,746.25 in the previous year[12]. - The company reported a total comprehensive income of ¥937,132,809.29 for the first half of 2021, compared to a loss of ¥102,201,746.25 in the previous year[131]. - The company’s net profit attributable to shareholders for the first half of 2021 was CNY 937,132,809.29, reflecting a strong performance compared to previous periods[142]. Research and Development - The company has allocated RMB 200 million for R&D in 2021, focusing on innovative vaccine technologies[1]. - The company invested 27.49% of its revenue in research and development, a decrease of 2,653.40 percentage points compared to the previous year[13]. - R&D expenses totaled approximately ¥566.73 million, a significant increase of 424.61% compared to the previous period[30]. - The company is focused on developing innovative vaccines, with a pipeline that includes vaccines for COVID-19, Ebola, meningitis, pneumonia, tuberculosis, and shingles[16]. - The company has a robust pipeline with 16 vaccine candidates across 13 disease areas, addressing the substantial unmet demand in the domestic vaccine market[37]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 15% market share by the end of 2022[1]. - The company is focused on commercializing its products, which has significantly contributed to its revenue growth[12]. - The company continues to expand its market presence and enhance its product offerings through ongoing research and development efforts[12]. - The company aims to improve the product structure of the domestic vaccine market as it continues to invest in new product development[19]. - The company plans to continue expanding its market presence and investing in new technologies and products to drive future growth[141]. Financial Health and Investments - Total assets increased by 51.92% to CNY 10,251,536,953.90 compared to the end of the previous year[12]. - The net assets attributable to shareholders rose by 15.57% to CNY 7,016,380,898.71, primarily due to profitability in the first half of the year[12]. - The company’s total financial assets measured at fair value increased to RMB 1,979,349,008.90 as of June 30, 2021, compared to RMB 666,639,616.43 at the end of 2020[59]. - The company’s cash flow from financing activities was CNY 1,151,794,769.02, primarily due to investments from minority shareholders and short-term loans[51]. - The company has reported a cumulative investment of CNY 15.36 million in vaccine research and development projects[112]. Regulatory and Risk Factors - Risk factors include potential regulatory changes and competition in the vaccine market, which could impact future performance[1]. - The implementation of the Vaccine Administration Law has strengthened regulatory oversight across all aspects of the vaccine industry, enhancing safety management and quality control[21]. - Regulatory changes in the vaccine industry could impact operations, necessitating timely adjustments to business strategies[48]. - The competitive landscape in the vaccine industry is intensifying, with potential risks from larger multinational companies and new entrants[47]. Environmental Responsibility - The company has established an environmental management system, including chemical usage, waste management, and laboratory waste handling principles[67]. - The company promotes resource efficiency through lean management and green office initiatives, optimizing energy and water usage[70]. - The company has committed to reducing carbon emissions through various measures, although specific results were not disclosed[71]. - Major pollutants generated during production include wastewater, waste gas, non-hazardous waste, and hazardous waste, with specific treatment measures in place for each category[68]. - The company has received a pollution discharge permit from the Tianjin Economic and Technological Development Zone Environmental Protection Bureau[67]. Shareholder Commitments and Governance - The company has a 36-month lock-up period for major shareholders following the A-share listing, ensuring stability in shareholding[72]. - The company commits to not transferring or managing shares held prior to the IPO for 12 months post-listing[81]. - The company will ensure compliance with the Shanghai Stock Exchange's regulations regarding share reduction by shareholders and executives[79]. - Any violations of these commitments by the actual controllers or executives will result in legal responsibilities for any losses incurred by the company or investors[74][76][77][79]. - The company will publicly explain any failure to meet commitments and apologize to investors[95].

Financial Performance - Operating revenue surged to CNY 466,758,070.10, a remarkable increase of 11,483.21% year-on-year[5] - The company reported a net loss of ¥15,751,950.02, a decrease of 31.82% compared to the previous year, mainly due to the positive impact of increased main business revenue on net loss[14] - The net loss for Q1 2021 was ¥15,751,950.02, an improvement from a net loss of ¥23,102,574.29 in Q1 2020[23] - Total comprehensive income for Q1 2021 was negative CNY 12,774,383.15, an improvement from negative CNY 23,100,310.37 in Q1 2020[28] Assets and Liabilities - Total assets increased by 11.49% to CNY 7,523,166,742.99 compared to the end of the previous year[5] - The total current assets as of March 31, 2021, amounted to approximately ¥5.81 billion, an increase from ¥5.42 billion as of December 31, 2020, representing a growth of about 7%[17] - Total liabilities rose to ¥1,189,920,589.15 in Q1 2021, up from ¥677,219,551.36 in Q1 2020[21] Cash Flow - Net cash flow from operating activities improved to CNY -12,415,330.54 from CNY -45,362,104.77 year-on-year[5] - The company experienced a net cash inflow from investment activities of ¥8,094,413.75, a change from the previous year's cash outflow, primarily due to the redemption of structured deposits[15] - The net cash inflow from financing activities was ¥228,283,550.03, a significant increase from the previous year's cash outflow, mainly due to short-term borrowings and cash received from minority shareholders' investments[15] - The company generated CNY 363,358,068.51 in cash from sales of goods and services in Q1 2021, compared to CNY 131,995.40 in Q1 2020[29] Research and Development - Research and development expenses accounted for 57.80% of operating revenue, a decrease of 923.25 percentage points compared to the previous year[6] - Research and development expenses increased by ¥230,255,643.34, a growth of 582.44%, as the company continued to increase R&D investment to maintain future product technology and quality advantages[14] - The company has ongoing research and development efforts for new products and technologies, particularly in the vaccine sector[16] Shareholder Information - The total number of shareholders at the end of the reporting period was 15,414[8] - The largest shareholder, HKSCC NOMINEES LIMITED, held 39.63% of the shares[8] Market Strategy - The company is focused on expanding its market presence and enhancing its product development strategies[5] - The company is exploring market expansion opportunities and potential mergers and acquisitions to enhance its growth strategy[16] Inventory and Receivables - Accounts receivable increased by ¥178,137,933.25, a growth of 804.47%, mainly due to the increase in accounts receivable resulting from the company's main business revenue[13] - Inventory rose by ¥169,680,211.36, an increase of 99.51%, primarily due to the increase in raw materials and turnover materials for research and production during the reporting period[13]

Financial Performance - The company's operating revenue for 2020 was CNY 24,890,414.09, a significant increase from CNY 2,283,391.88 in 2019, representing a growth of 1,087.67%[16]. - The net profit attributable to shareholders for 2020 was a loss of CNY 396,638,192.10, compared to a loss of CNY 156,781,479.69 in 2019, marking an increase in losses of 152.99%[16]. - The net cash flow from operating activities for 2020 was a negative CNY 349,933,694.99, which is a 126.86% increase in cash outflow compared to the previous year[16]. - The total assets at the end of 2020 amounted to CNY 6,748,073,711.72, reflecting a 278.15% increase from CNY 1,784,498,716.49 at the end of 2019[16]. - The net assets attributable to shareholders at the end of 2020 were CNY 6,070,854,160.36, which is a 312.84% increase from CNY 1,470,516,717.61 at the end of 2019[16]. - The basic and diluted earnings per share for 2020 were both -RMB 1.72, representing a 126.32% increase in losses compared to RMB -0.76 in 2019[17]. - The weighted average return on equity was -13.49% for 2020, a decrease of 1.01 percentage points from the previous year[17]. - The company reported a cumulative unremitted loss of -764.69 million RMB as of the reporting period[67]. Research and Development - R&D expenses significantly increased as the company continued to advance its clinical trials and product development amid the pandemic[18]. - The company increased its R&D investment significantly, with a total of ¥428,485,740.26 in the current year, representing a 182.37% increase compared to ¥151,745,949.20 in the previous year[47]. - The company’s R&D pipeline includes vaccines for high-demand clinical needs such as COVID-19, meningitis, and tuberculosis, with several products in clinical trial stages[35]. - The company has established four leading core technology platforms, including polysaccharide-protein conjugate technology and adenovirus vector vaccine technology, enhancing its competitive advantage in the domestic market[36]. - The company has made significant progress in clinical trials for its pipeline products, leading to an increase in R&D investment[94]. - The company has completed the Phase I clinical trial for the Ad5-nCoV recombinant COVID-19 vaccine, with the first volunteer injected on March 2020 and the trial endpoints achieved[86]. - The company has completed the Phase I clinical trial for the DTcP vaccine for infants, which started in April 2020, focusing on safety in children aged 2 months to 6 years[86]. - The company has completed the Phase I clinical trial for the PCV13i vaccine, initiated in May 2020, aimed at assessing safety and immunogenicity in healthy individuals aged 2 months and older[87]. Market Strategy and Expansion - The company is actively pursuing market expansion strategies to increase its presence in both domestic and international markets[15]. - The company has established partnerships with several research institutions and companies to enhance its vaccine development capabilities[15]. - The company has established a core marketing team covering over ten major provincial markets in China, including Jiangsu and Guangdong, in preparation for product commercialization[29]. - The company plans to rapidly expand its commercialization team and enhance academic promotion efforts to increase public awareness of vaccines, which is expected to positively impact vaccine sales[109]. - The company aims to establish a marketing system primarily based on its own sales team, with plans to collaborate with professional promoters to penetrate county-level markets[109]. Corporate Governance - The company has received a standard unqualified audit report from PwC Zhongtian[5]. - The company has not engaged in any non-operational fund occupation by controlling shareholders or related parties[5]. - The company has not violated decision-making procedures for external guarantees[5]. - The company has not disclosed any special arrangements for corporate governance[5]. - The company’s board of directors was fully present at the board meeting[5]. - The company has not reported any instances where more than half of the directors could not guarantee the accuracy of the annual report[5]. - The company has confirmed that all commitments made by shareholders and actual controllers have been strictly adhered to during the reporting period[114]. Regulatory Environment - The introduction of the Vaccine Administration Law on December 1, 2019, has strengthened regulatory oversight across all aspects of the vaccine industry, including R&D, production, distribution, and sales[38]. - The regulatory environment is expected to further tighten, increasing survival pressure on smaller vaccine companies lacking core R&D capabilities[39]. - The company will comply with relevant laws and regulations regarding shareholding and changes in shareholding of controlling shareholders and actual controllers[118]. Shareholder Commitments - The company has committed to a 36-month lock-up period for major shareholders and actual controllers starting from the date of A-share listing[114]. - The company has outlined specific conditions under which the lock-up period for shares may be extended by 6 months[116]. - The company has established a policy that limits the annual transfer of shares by directors and senior management to no more than 25% of their total holdings after the lock-up period[117]. - The company guarantees that the IPO does not involve any fraudulent issuance and will initiate a buyback of shares if it fails to meet listing conditions[132]. - The controlling shareholder also guarantees the absence of fraudulent issuance in the IPO process and commits to a buyback if necessary[133]. Social Responsibility - The company donated over RMB 40,000 worth of epidemic prevention materials to support local pandemic control efforts[171]. - The company has implemented measures to manage and treat waste, including partnerships with qualified waste disposal companies[173]. Financial Management - The company has engaged in structured deposits with various banks, including a total of 800,000,000.00 RMB with Shanghai Pudong Development Bank, maturing on December 30, 2020[157]. - The annualized return rate for structured deposits ranges from 2.60% to 3.85%[156]. - The company has confirmed that all transactions with Tianjin TEDA Technology Development Group Co., Ltd. are not related party transactions[153].